Nirmatrelvir/ritonavir, sold under the brand name Paxlovid, is a co-packaged medication used as a treatment for COVID‑19. It contains the antiviral medications...

Nirmatrelvir is an antiviral medication developed by Pfizer which acts as an orally active 3C-like protease inhibitor. It is part of a nirmatrelvir/ritonavir...

enhance their blood concentration. In December 2021, the combination of nirmatrelvir and ritonavir was granted emergency use authorization by the US Food...

respiratory syndrome coronavirus 2) inhibitors—class stem –trelvir Ensitrelvir Nirmatrelvir Simnotrelvir Given the specificity of the target of these drugs there...

COVID‑19. It contains the antiviral medications nirmatrelvir and ritonavir and was developed by Pfizer. Nirmatrelvir inhibits SARS-CoV-2 main protease, while...

second-generation improvement over nirmatrelvir which has a similar chemical structure. One of the disadvantages of nirmatrelvir is that it has low metabolic...

medication nirmatrelvir (formerly PF-07321332) became commercially available under emergency use authorizations (EUA), as part of the nirmatrelvir/ritonavir...

Use (CHMP) approved the oral antiviral protease inhibitor, Paxlovid (nirmatrelvir plus the HIV antiviral ritonavir), to treat adult patients. FDA later...

moderate symptoms who are in the risk groups[needs update] can take nirmatrelvir/ritonavir (marketed as Paxlovid) or remdesivir, either of which reduces...

December 2021, the United States granted emergency use authorization to Nirmatrelvir/ritonavir for the treatment of the virus; the European Union, United...